Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer
NCT ID: NCT00899002
Last Updated: 2013-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2007-07-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is looking at biomarkers in stored tumor samples from younger patients with liver cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Tissue Samples From Young Patients With Liver Cancer
NCT01336881
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
NCT00898664
Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers
NCT00899769
Genetic Studies in Liver Cancer Patients
NCT00172640
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
NCT00904514
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To characterize, at a molecular level, archived samples of tissue from young patients with fibrolamellar carcinoma and hepatocellular carcinoma in non-cirrhotic livers matched for age and sex.
* To perform genomic analysis on these tissue samples using array comparative genomic hybridization.
* To perform targeted gene mutation analysis on these samples by PCR.
* To perform proteomic profiling on fixed tissues in these samples by various proteomic methods, including IHC and mass spectrometry.
* To look for association between molecular aberrations and clinicopathologic features in these samples.
OUTLINE: Archived tissue samples are collected from the pathology department at Vanderbilt University Medical Center and from the Mayo Clinic in Rochester, Minnesota. Tissue samples are analyzed by genomic analysis using array comparative genomic hybridization, target gene mutation analysis by PCR, and proteomic profiling on fixed tissues using various proteomic methods, including IHC and mass spectrometry. Samples are also examined for association between molecular aberrations and clinicopathologic features found in each disease.
Clinical patient data (i.e., age, sex, race, date of diagnosis, risk factors, histology, surgical staging, follow-ups, date of death, and adjuvant therapy) are also collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
comparative genomic hybridization
molecular genetic technique
mutation analysis
polymerase chain reaction
Not noted
proteomic profiling
immunohistochemistry staining method
not noted
laboratory biomarker analysis
not noted
mass spectrometry
not noted
medical chart review
not noted
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of fibrolamellar carcinoma or hepatocellular carcinoma in a non-cirrhotic liver
* Archived tumor specimens available for analysis from Vanderbilt University or Mayo Clinic
Exclusion Criteria
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Laura W. Goff, MD
Assistant Professor of Medicine, Medical Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura Goff, MD
Role: STUDY_CHAIR
Vanderbilt-Ingram Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VU-VICC-GI-0611
Identifier Type: -
Identifier Source: secondary_id
VU-VICC-060479
Identifier Type: -
Identifier Source: secondary_id
VICC GI 0611
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.